0001567619-19-017492.txt : 20190822 0001567619-19-017492.hdr.sgml : 20190822 20190822180152 ACCESSION NUMBER: 0001567619-19-017492 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190821 FILED AS OF DATE: 20190822 DATE AS OF CHANGE: 20190822 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ALSTODT LANCE CENTRAL INDEX KEY: 0001756228 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37603 FILM NUMBER: 191046806 MAIL ADDRESS: STREET 1: BIORESTORATIVE THERAPIES, INC. STREET 2: 40 MARCUS DRIVE, SUITE 1 CITY: MELVILLE STATE: NY ZIP: 11747 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BioRestorative Therapies, Inc. CENTRAL INDEX KEY: 0001505497 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 911835664 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 40 MARCUS DRIVE CITY: MELVILLE STATE: NY ZIP: 11747 BUSINESS PHONE: (631) 760-8100 MAIL ADDRESS: STREET 1: 40 MARCUS DRIVE CITY: MELVILLE STATE: NY ZIP: 11747 FORMER COMPANY: FORMER CONFORMED NAME: Stem Cell Assurance, Inc. DATE OF NAME CHANGE: 20101110 4 1 doc1.xml FORM 4 X0306 4 2019-08-21 0 0001505497 BioRestorative Therapies, Inc. BRTX 0001756228 ALSTODT LANCE C/O BIORESTORATIVE THERAPIES, INC. 40 MARCUS DRIVE, SUITE 1 MELVILLE NY 11747 0 1 0 0 EVP and Chief Strategy Officer Common Stock 2019-08-21 4 P 0 100 .23 A 100 D Common Stock 2019-08-21 4 P 0 9900 .25 A 10000 D Stock Option .75 2028-10-15 Common Stock 500000 500000 D The option vests to the extent of 100,000 shares as of October 15, 2018, 150,000 shares upon the earlier of October 15, 2019 or the date on which the initial patient recruitment for the Company's Phase II lumbar clinical trial occurs, and 250,000 shares as of October 15, 2020. /s/ Lance Alstodt 2019-08-22